Drug Trial Radar · NCT04241549
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Mar 25, 2020
Primary completion
Jul 19, 2021
Study completion Jul 19, 2021
Sponsor
- Lead sponsor
- OncoVerity, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- argenx; Janssen Pharmaceutical K.K.
- First posted
- Jan 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the recommended Phase 2 dose and evaluate safety profile of cusatuzumab in combination with azacitidine in Japanese participants with treatment naïve acute myeloid leukemia (AML) who are not candidates for intensive treatment.
Conditions
- Leukemia, Myeloid, Acute
Interventions
CusatuzumabDrug
Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.
AzacitidineDrug
Azacitidine at a dose 75 milligram per square meters (mg/m\^2) will be administered subcutaneously or intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 and Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 3 years
- Part 1 and Part 2: Number of Participants with Dose-Limiting Toxicity (DLTs)Time frame: Up to 42 days
- Part 1 and Part 2: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)Time frame: Up to 42 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Fukushima Medical University Hospital
Fukushima, Japan
Gunmaken Saiseikai Maebashi Hospital
Maebashi, Japan
Osaka City General Hospital
Osaka, Japan
NTT Medical Center Tokyo
Tokyo, Japan
University of Fukui Hospital
Yoshida, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.